{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:30:24Z","timestamp":1786710624795,"version":"build-2736575974"},"reference-count":19,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>INTRODUCTION. PIONEER REAL Denmark assessed changes in HbA1c, body weight and treatment satisfaction with once-daily oral semaglutide in adults with type 2 diabetes.\n\nMETHODS. In this multicentre, prospective, open-label, non-interventional study, participants initiated oral semaglutide in routine clinical practice and were followed up for 34-44 weeks. The primary endpoint was change in HbA1c from baseline to the end of study (EOS). Secondary endpoints assessed at EOS included change in body weight (BW), proportion of participants reaching HbA1c &lt; 7% and treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire status\/change (DTSQs\/DTSQc).\n\nRESULTS. In total, 96 participants from a primary care setting were included (median age: 63.5 years, HbA1c: 7.6% (60.0 mmol\/mol), BW: 97.4 kg). Estimated changes from baseline to EOS in HbA1c (n = 96) and BW (n = 86) were \u22120.9 percentage points (9.9 mmol\/mol) (95% CI: \u22121.20; \u22120.61 percentage points) and \u22124.4 (95% CI: \u22125.44; \u22123.41) kg, respectively. At baseline, 28.1% of participants had HbA1c &lt; 7.0% (&lt; 53 mmol\/mol); at EOS, 66.7% of participants had HbA1c &lt; 7.0% (53 mmol\/mol). Improvements in treatment satisfaction were observed in DTSQs (1.9 points) and DTSQc (10.5 points) scores. No new safety signals were identified for oral semaglutide.\n\nCONCLUSIONS. In PIONEER REAL Denmark, participants treated with oral semaglutide in a primary care setting experienced reductions in HbA1c and BW.\n\nFUNDING. This study was sponsored by Novo Nordisk A\/S.\n\nTRIAL REGISTRATION. ClinicalTrials.gov (NCT04537637).<\/jats:p>","DOI":"10.61409\/a06250520","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:41:43Z","timestamp":1783075303000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of oral semaglutide in adults with type 2 diabetes"],"prefix":"10.61409","author":[{"given":"Klaus","family":"Roslind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Bodholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Damgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2016,6]]},"reference":[{"key":"ref0","unstructured":"Diabetesforeningen. Diabetestal. Diabetesforeningen, 2024. www.diabetestal.nu\/ (8 Oct 2024)"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Thomsen RW, Friborg S, Nielsen JS, et al. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants. Clin Epidemiol. 2012;4(suppl 1):15-19. https:\/\/doi.org\/10.2147\/CLEP.S30082","DOI":"10.2147\/CLEP.S30082"},{"key":"ref2","unstructured":"US Food and Drug Administration. Ozempic Prescribing Information. US Food and Drug Administration, 2017. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf (20 Jun 2024)"},{"key":"ref3","unstructured":"European Medicines Agency. Ozempic Summary of Product Characteristics. European Medicines Agency, 2018. www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf (20 Jun 2024)"},{"key":"ref4","unstructured":"European Medicines Agency. Rybelsus Summary of Product Characteristics. European Medicines Agency, 2025. www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf (3 Oct 2025)"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Nielsen MS, Br\u00f8nsted L, Kankam M, et al. A bioequivalence study of two formulations of oral semaglutide in healthy participants. Diabetes Ther. 2025;16(2):269-287. https:\/\/doi.org\/10.1007\/s13300-024-01674-8","DOI":"10.1007\/s13300-024-01674-8"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Rudofsky G, Amadid H, Braae UC, et al. Oral semaglutide use in type 2 diabetes: a pooled analysis of clinical and patient-reported outcomes from seven PIONEER REAL prospective real-world studies. Diabetes Ther. 2025;16(1):73-87. https:\/\/doi.org\/10.1007\/s13300-024-01668-6","DOI":"10.1007\/s13300-024-01668-6"},{"key":"ref7","unstructured":"Danish Society for General Practice. Pharmacological treatment of type 2 diabetes: aims and algorithms 2018. Danish Society for General Practice, 2018. www.dsam.dk\/vejledninger\/fb-type2\/farmakologisk-behandling-af-hyperglykaemi#behandlingsmaal (10 Dec 2024)"},{"key":"ref8","unstructured":"Danish Endocrinological Society. Type 2 diabetes. Danish Endocrinological Society, 2024. https:\/\/endocrinology.dk\/nbv\/diabetes-melitus\/behandling-og-kontrol-af-type-2-diabetes\/ (29 Oct 2025)"},{"key":"ref9","unstructured":"Bradley C. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Harwood Academic Publishers, 1994"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999;22(3):530-532. https:\/\/doi.org\/10.2337\/diacare.22.3.530","DOI":"10.2337\/diacare.22.3.530"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263-1277. https:\/\/doi.org\/10.1111\/dom.14054","DOI":"10.1111\/dom.14054"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Aroda VR, Faurby M, Lophaven S, et al. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab. 2021;23(9):2177-2182. https:\/\/doi.org\/10.1111\/dom.14453","DOI":"10.1111\/dom.14453"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hu J, Hu Y, Hertzmark E, et al. Weight change, lifestyle, and mortality in patients with type 2 diabetes. J Clin Endocrinol Metab. 2022;107(3):627-637. https:\/\/doi.org\/10.1210\/clinem\/dgab800","DOI":"10.1210\/clinem\/dgab800"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154. https:\/\/doi.org\/10.1056\/NEJMoa1212914","DOI":"10.1056\/NEJMoa1212914"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med. 2004;117(10):762-774. https:\/\/doi.org\/10.1016\/j.amjmed.2004.05.024","DOI":"10.1016\/j.amjmed.2004.05.024"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"de Fine Olivarius N, Siersma VD, K\u00f8ster-Rasmussen R, et al. Weight changes following the diagnosis of type 2 diabetes: the impact of recent and past weight history before diagnosis. Results from the Danish Diabetes Care in General Practice (DCGP) study. PLoS One. 2015;10(4):e0122219. https:\/\/doi.org\/10.1371\/journal.pone.0122219","DOI":"10.1371\/journal.pone.0122219"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528-539. https:\/\/doi.org\/10.1016\/S2213-8587(19)30194-9","DOI":"10.1016\/S2213-8587(19)30194-9"},{"key":"ref18","unstructured":"GPP. GPP 2022 guidelines. https:\/\/www.ismpp.org\/gpp-2022 (20 May 2026)"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:32:01Z","timestamp":1786707121000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A06250520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":19,"URL":"https:\/\/doi.org\/10.61409\/a06250520","relation":{},"ISSN":["2245-1919"],"issn-type":[{"value":"2245-1919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}